Aimmune Therapeutics Inc (NASDAQ:AIMT) saw some unusual options trading activity on Thursday. Stock traders acquired 2,787 call options on the company. This is an increase of approximately 1,653% compared to the typical volume of 159 call options.

Several hedge funds and other institutional investors have recently made changes to their positions in AIMT. Wells Fargo & Company MN grew its position in shares of Aimmune Therapeutics by 7.6% in the first quarter. Wells Fargo & Company MN now owns 67,954 shares of the biotechnology company’s stock valued at $2,163,000 after purchasing an additional 4,796 shares during the period. American Century Companies Inc. grew its position in shares of Aimmune Therapeutics by 38.9% in the first quarter. American Century Companies Inc. now owns 121,577 shares of the biotechnology company’s stock valued at $3,870,000 after purchasing an additional 34,062 shares during the period. Victory Capital Management Inc. grew its position in shares of Aimmune Therapeutics by 936.4% in the first quarter. Victory Capital Management Inc. now owns 664,641 shares of the biotechnology company’s stock valued at $21,155,000 after purchasing an additional 600,510 shares during the period. State Board of Administration of Florida Retirement System grew its position in shares of Aimmune Therapeutics by 24.2% in the first quarter. State Board of Administration of Florida Retirement System now owns 14,637 shares of the biotechnology company’s stock valued at $466,000 after purchasing an additional 2,854 shares during the period. Finally, Massachusetts Financial Services Co. MA acquired a new stake in shares of Aimmune Therapeutics in the first quarter valued at about $7,110,000. Institutional investors and hedge funds own 78.16% of the company’s stock.

A number of research analysts have weighed in on the stock. ValuEngine raised shares of Aimmune Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Tuesday, May 22nd. Wedbush reaffirmed an “outperform” rating and issued a $72.00 price objective on shares of Aimmune Therapeutics in a report on Wednesday, May 30th. BidaskClub raised shares of Aimmune Therapeutics from a “hold” rating to a “buy” rating in a report on Wednesday, May 30th. Credit Suisse Group set a $47.00 price objective on shares of Aimmune Therapeutics and gave the company a “buy” rating in a report on Tuesday, June 12th. Finally, Piper Jaffray Companies assumed coverage on shares of Aimmune Therapeutics in a report on Friday, May 18th. They issued an “overweight” rating and a $30.01 price objective for the company. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and nine have assigned a buy rating to the company’s stock. Aimmune Therapeutics has an average rating of “Buy” and a consensus price target of $52.89.

Shares of NASDAQ AIMT opened at $29.20 on Friday. Aimmune Therapeutics has a 52-week low of $22.85 and a 52-week high of $42.00. The stock has a market capitalization of $1.70 billion, a PE ratio of -11.19 and a beta of -0.28.

Aimmune Therapeutics (NASDAQ:AIMT) last announced its earnings results on Wednesday, August 8th. The biotechnology company reported ($0.91) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.86) by ($0.05). sell-side analysts forecast that Aimmune Therapeutics will post -3.63 EPS for the current year.

Aimmune Therapeutics Company Profile

Aimmune Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy product candidate is AR101, an investigational biologic for the treatment of patients with peanut allergy.

Recommended Story: Tariff

Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.